WHO vaccine safety committee publishes updated immunization policy guidance

The World Health Organization's Global Advisory Committee on Vaccine Safety released new guidance on March 13, 2026, addressing current vaccine safety policies and immunization-related issues facing member states. The GACVS was established in 1999 as an independent scientific body that advises the WHO on vaccine safety questions. Its guidance does not carry the force of law, but national health ministries, regulatory agencies, and immunization programs around the world routinely use its recommendations to shape their own policies.

The timing of this release is not incidental. The WHO has identified vaccine hesitancy as one of the top ten threats to global health, and the data from 2025 and early 2026 has made that concern more concrete. Global measles cases were rising before the current US outbreak, and polio has re-emerged in countries that previously had it under control. Immunization programs that worked well for decades are now operating in a social environment where public trust in vaccines has declined measurably in multiple high-income countries.

What GACVS does and how its guidance works

GACVS is composed of 14 independent scientific experts appointed by the WHO Director-General, drawn from fields including epidemiology, clinical medicine, immunology, and pharmacovigilance. Members serve in their personal capacity rather than as representatives of their governments or employers, which is intended to insulate the committee's conclusions from national political pressures. The committee meets twice per year under normal circumstances and convenes additional sessions when safety signals require urgent assessment.

When GACVS publishes guidance, it is drawing on a systematic review of published literature, spontaneous adverse event reports submitted through national pharmacovigilance systems, and data from vaccine manufacturers submitted to the WHO's prequalification process. The committee does not conduct its own clinical trials. Its role is to synthesize and evaluate existing evidence and communicate conclusions in a format that national regulators and health ministries can act on. This makes the quality of the underlying surveillance data fed into the system as important as the committee's own analysis.

The vaccine hesitancy context the guidance addresses

The WHO's 2019 identification of vaccine hesitancy as a top global health threat was made before COVID-19. The pandemic significantly complicated the picture. On one hand, mRNA vaccine technology was deployed globally at a speed and scale that had never been attempted, producing genuinely new safety questions that required active monitoring. On the other hand, the social media environment around COVID-19 vaccines produced a wave of misinformation that did not stay contained to COVID vaccines. By 2023, surveys by the Wellcome Trust found that confidence in vaccines had declined in 52 countries compared to pre-pandemic levels, with the steepest drops in some Western European nations.

In the United States specifically, a 2024 KFF Health Tracking Poll found that 26 percent of American adults believed vaccines caused autism, a claim that has been thoroughly and repeatedly refuted in large-scale epidemiological studies, including a 2019 Danish cohort study of 650,000 children that found no association between the MMR vaccine and autism. That belief, now held by more than one in four American adults, has direct consequences for vaccination coverage rates that are visible in the 2026 measles outbreak data.

Key areas the updated GACVS guidance covers

The March 13 guidance document covers several specific areas. It includes updated recommendations on pharmacovigilance systems, the infrastructure countries use to detect and report adverse events following immunization. It addresses communication strategies for health authorities responding to vaccine safety concerns, drawing on evidence about what types of messaging reduce hesitancy versus what types inadvertently amplify it. The guidance also addresses specific safety signals that have emerged from recent vaccine deployments, including updated assessments of myocarditis associated with mRNA COVID vaccines in adolescent males, where the GACVS reaffirmed that the benefit-risk balance of vaccination remains favorable across all age groups.

The myocarditis signal is worth addressing specifically because it has been one of the most frequently cited claims in vaccine hesitancy conversations online. The CDC's VAERS system and the active surveillance conducted through the CDC's Vaccine Safety Datalink confirmed that mRNA COVID vaccines do carry a small elevated risk of myocarditis, particularly in males aged 12 to 17 after the second dose, with rates of approximately 39 cases per million doses in that demographic. The GACVS assessment, consistent with CDC and European Medicines Agency conclusions, is that this risk is substantially lower than the cardiac complications associated with COVID-19 infection in the same age group.

Why the guidance matters for member states dealing with hesitancy

National health ministries that are trying to respond to declining vaccination rates need credible, current safety assessments that they can communicate to the public and to healthcare providers who are fielding questions from hesitant patients. A family doctor who wants to address a parent's concerns about vaccine safety needs to be working from the same evidence base as the GACVS, not from outdated literature or from information circulating on social platforms. The updated guidance serves as a reference document for that communication chain.

Several countries have already responded to declining coverage by changing their immunization programs in ways GACVS recommendations informed. Australia tightened its No Jab No Pay policy in 2016, linking childcare subsidies to vaccination compliance, and saw measles coverage among children under five rise from 92 percent in 2015 to 94.6 percent by 2019 according to the Australian Institute of Health and Welfare. The GACVS guidance does not prescribe policy responses of that kind, but it provides the safety evidence base that allows governments to justify such policies to the public. The committee's next scheduled meeting is in June 2026, where it will assess any new safety signals that have emerged since the March publication.